Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China-Reference-Cited by-同舟云学术

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China

Published:2022-03 Issue: Volume:Volume 17 Page:609-619
ISSN:1178-2005
Container-title:International Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD

Author:

Lan Ying,Yang Nan,Wang Yirong,Yang Yujie,Xu Min,He Qin

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine

Reference25 articles.

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020 [Updated 2021]. Available from: https://goldcopd.org/2021-gold-reports/. Accessed October 21, 2021.

2. A Subnational Analysis of Mortality and Prevalence of COPD in China From 1990 to 2013

3. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study

4. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

5. Disease burden of COPD in China: a systematic review

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China;Respiratory Medicine;2024-05

2. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials;Postgraduate Medical Journal;2024-04-23